ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0071 • ACR Convergence 2025

    Unravelling Transcriptomic Landscapes in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Shared and Unique Molecular Signatures related to relevant clinical features.

    Chary López pedrera1, Tomás Cerdó2, Ismael Sanchez-Pareja2, Daniel Toro3, MARIA ANGELES AGUIRRE ZAMORANO2, Elena Moreno-Caño4, Laura muñoz-Barrera2, Sagrario Corrales2, Rafaela Ortega-Castro5, Concepción Aranda-Valera6, Lourdes Ladehesa7, Jerusalén Calvo6, Pilar Font8, M Carmen Abalos-Aguilera9, Desiree Ruiz-Vilchez10, Christian Merlo-Ruiz9, Nuria Barbarroja11, Carlos Pérez Sánchez12, Marta Alarcon-Riquelme13 and Alejandro Escudero Contreras6, 1Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 2Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 3GENYO / Karolinska Institutet, Granada / Stockholm, Spain, 4IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, 5Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, 6IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, 7IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, 8Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, SpainBiomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 9Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 10Department of Rheumatology, Reina Sofía University Hospital / Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) / Department of Medical and Surgical Sciences, Faculty of Medicine, University of Córdoba, Spain, Cordoba, Spain, 11Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 12Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, 13Fundación Progreso y Salud, Andalusian Government, Granada, Spain

    Background/Purpose: This study aimed to identify shared and distinct gene and protein expression profiles associated with clinical features in rheumatoid arthritis (RA), systemic lupus erythematosus…
  • Abstract Number: 0048 • ACR Convergence 2025

    Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting

    Xue Wang1, Fei Wang2, Sílvia Sisó2, Archana Iyer2, Heather Knight2, Lori Duggan2, Yingli Yang2, Liang Jin2, Baoling Cui2, Yupeng He3, Jan Schejbal2, Lucy Phillips2, Bohdan Harvey4 and Yu Tian2, 1AbbVie, South San Francisco, CA, 2AbbVie, Worcester, MA, 3AbbVie, North Chicago, IL, 4AbbVie, Cambridge, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, fibroblast proliferation and progressive joint damage. Understanding the heterogeneity of RA and…
  • Abstract Number: L10 • ACR Convergence 2024

    Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

    John Tesser1, Joshua June2, Pendleton Wickersham3, Jane Box4, Guillermo Valenzuela5, Angela Crowley6, Nikila Kumar7, Norman Gaylis8, Gordan Lam9, David Ridley10, Gineth Paola Pinto-Patarroyo11 and David Chernoff12, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Great Lakes Center of Rheumatology, Lansing, MI, 3Arthritis Associates PA, San Antonio, TX, 4DJL Clinical Research, PLLC, Charlotte, NC, 5Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 6Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 7Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, 8Arthritis & Rheumatic Disease Specialties, Aventura, FL, 9Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, 10St. Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Fairfax, VA, 12SetPoint Medical, Sausalito, CA

    Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
  • Abstract Number: L12 • ACR Convergence 2024

    A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity

    Chunli Mei1, Xin Guan1, Bin Wu2, Mengjiao Li1, Xiaojing Liu1, Xi Chen1, You Song1, Weiwei Wang1, Cheng Wang1, Huiling Mei1, Xiaoru Duan1, Lijuan Jiang1, Wenlin Qiu1, Likai Yu1, Yuhong Liu1, Xing Zhao3, Xuanfan Zhong3, Shengjie Xue3, Wuzhong Shen3, Ying Tan3, Guojian Yu3, Guiyun Tu3, Hanyang Chen3, Amy Sun3, Xiaoqiang Yan3, Anbing Huang1, Rong Du1 and Qiubai Li1, 1Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, 3ITabMed Ltd. Changchun, Shanghai, China

    Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
  • Abstract Number: L20 • ACR Convergence 2024

    Automated Ultrasound System ARTHUR with AI Analysis DIANA Matches Expert Rheumatologist in Hand Joint Assessment of Rheumatoid Arthritis Patients

    Bill Aplin Frederiksen1, Mads Ammitzbøll Danielsen2, Hilde Berner Hammer3, Benjamin Schultz Overgaard1, Anders Weber4, Lene Terslev2, Thiusius Rajeeth Savarimuthu5 and Soren Andreas Just1, 1Section of Rheumatology, Department of Medicine, Svendborg Sygehus OUH, Svendborg, Denmark, 2Center for Rheumatology and Spine Disease, Rigshospitalet, Glostrup, Denmark, 3Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway, 4ROPCA, Odense, Denmark, 5Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, Odense, Denmark

    Background/Purpose: To evaluate the precision of ARTHUR (Figure 1), a CE-marked, fully automated ultrasound scanning system that captures ultrasound images of 22 hand joints and…
  • Abstract Number: 0033 • ACR Convergence 2024

    Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles

    Linda Mathsson-Alm1, Helga Westerlind2, Isabel Gehring3, Monika Hansson2, Nasim Ghasemzadeh1, Jessica Rojas-Restrepo3, Saedis Saevarsdottir4, Joseph Sexton5, Siri Lillegraven6, Espen Haavardsholm6, Merete Hetland7, Hilde Hammer8, Tore K. Kvien9, Bente Glintborg10, Leonid Padyukov2, Johan Askling2 and Caroline Grönwall2, and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), 1Thermo Fisher Scientific, Uppsala, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Thermo Fisher Scientific, Freiburg, Germany, 4University of Iceland, Reykjavik, Iceland, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Diakonhjemmet Hospital, Oslo, Norway, 7Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 8Diakonhjemmet Hospital, Oslo, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark

    Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
  • Abstract Number: 0049 • ACR Convergence 2024

    Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis

    Marcelo Afonso1, Jitong Sun1, Koji Sakuraba1, Alexandra Circiumaru2, Denis Lagutkin1, Masa Filipovic1, Anca Catrina1, Caroline Grönwall1, Aase Hensvold1 and Bence Réthi1, 1Karolinska Institutet, Stockholm, Sweden, 2Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden

    Background/Purpose: We have previously shown that autoantibodies targeting malondialdehyde-acetaldehyde protein adducts (anti-MAA) in rheumatoid arthritis (RA) patients boosted osteoclast differentiation and induced bone erosion in mice…
  • Abstract Number: 0079 • ACR Convergence 2024

    Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis

    Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2VA Medical Center Sacramento, Mather, CA, 3VA Sacramento Medical Center, Mather, CA

    Background/Purpose: Tissue-resident memory T cells (TRM) cells can drive localized, recurrent inflammation. TRM are site-specific T cells that take up long-term residence in peripheral tissues…
  • Abstract Number: 0187 • ACR Convergence 2024

    Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
  • Abstract Number: 0306 • ACR Convergence 2024

    Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis

    Aleydis Gonzalez Melendez1, Rebeca L. Polina-Lugo1, Maria F. Elizondo-Benitez2, Andrea Guajardo Aldaco1, Osvaldo Uresti3, Ricardo I. de la Rosa-Vazquez3, Iris Jazmín Colunga Pedraza1, Dionicio Galarza-Delgado4, jose Ramon Azpiri-Lopez5, Rosa Icela Arvizu-Rivera1 and Jesus Cardenas-de la Garza6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 6Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
  • Abstract Number: 0439 • ACR Convergence 2024

    Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences

    Laura Kobashigawa1, Cassidy Hernandez-Tamayo2, Katherine Ruddy3, Melissa Wilson2 and Leanna Wise4, 1University of Southern California/Los Angeles General Medical Center, Pasadena, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, 4LAC+USC/Keck Medicine of USC, Pasadena, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
  • Abstract Number: 0470 • ACR Convergence 2024

    New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers

    Veronica Pulito-Cueto1, Belén Atienza-Mateo2, gonzalo Ocejo-Viñals3, Victor M. Mora-Cuesta4, David Iturbe-Fernández4, Joao Carlos Batista-Liz1, María Sebastián Mora-Gil5, Mónica Renuncio-García6, Elena González López3, José M. Cifrián7, Ricardo Blanco-Alonso8 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, 4Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, 5Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, 6Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, 7Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of death in rheumatoid arthritis (RA) patients [1]. Early diagnosis of RA-ILD+ is critical…
  • Abstract Number: 0487 • ACR Convergence 2024

    The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis

    Jose Felix Restrepo Suarez1, Carlos Lorenzo1, Inmaculada Del rincon2 and Agustin Escalante1, 1UT Health San Antonio, San Antonio, TX, 2UT Health San Antonio, San Antonio

    Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…
  • Abstract Number: 0504 • ACR Convergence 2024

    Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database

    Linus Maximilian Risser1, Torsten Witte2, Matthias Englbrecht3, Patrick-Pascal Strunz4, Matthias Froehlich5, Marc Schmalzing6, Michael Gernert7, Peter Bartz-Bazzanella8, Cay von Der Decken9, Kirsten Karberg10, Georg Gauler11, Susanna Spaethling-Mestekemper12, Christoph Kuhn13, Wolfgang Vorbrueggen14, Martin Welcker15 and Stefan Kleinert16, 1Hannover Medical School, Hannover, Germany, 2Dept of Immunology and Rheumatology, Hannover, Germany, 3Freelance Healthcare Data Scientist, Eckental, 4University hospital of Wuerzburg, Wuerzburg, Germany, 5Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, 6University Hospital Wuerzburg, Würzburg, Germany, 7Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, 8Rhein-Maas Klinikum, Wuerselen, Germany, 9Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, 10Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, 11rheumapraxis, Osnabrück, Germany, 12Rheumapraxis Muenchen, Muenchen, Germany, 13Praxis für Rheumatologie, Karlsruhe, Germany, 14Verein zur Foerderung der Rheumatologie e.V, Wuerselen, Germany, 15Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, 16Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany

    Background/Purpose: Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept,…
  • Abstract Number: 0521 • ACR Convergence 2024

    Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis

    Ernest Choy1, Maria López Lasanta2, Paloma Vela-Casasempere3, Antonio Fernandez Nebro4, Santos Castañeda5, Carlos Marras6, Jaime Calvo-Alén7, Jesus Tornero8, Juan Cañete9, Eugeni Domènech10, Javier Gisbert11, José Manuel Carrascosa12, Eduardo Fonseca13, Luis Bujanda14, Valle García15, Britta Siegmund16, Giampiero Girolomoni17, Holger Heyn18, Pere Santamaria19, Richard M Myers20, yolanda Guillen21, Sergio H Martínez-Mateu22, Sara Marsal23 and Antonio Julia24, and IMID Consortium, 1Cardiff University School of Medicine, Cardiff, United Kingdom, 2Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, 3Hospital General Universitario Alicante, Alicante, Spain, 4Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 7Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 8Hospital Universitario de Guadalajara, Guadalajara, Spain, 9Hospital Clinic an IDIBAPS, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 11Hospital Universitario de la Princesa and IIS-IP, Madrid, Spain, 12Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 13Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 14Hospital Universitario de Donostia, San Sebastián, Spain, 15Hospital Universitario Reina Sofía, Córdoba, Spain, 16Charité – Universitätsmedizin Berlin, Berlin, Germany, 17University of Verona, Verona, Italy, 18Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, 19Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 20HudsonAlpha Institute for Biotechnology, Huntsville, AL, 21Imidomics, Inc, Barcelona, Spain, 22IMIDOMICs, Barcelona, Spain, 23Vall Hebron Hospital Research Institute, Barcelona, Spain, 24Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Targeted therapies have failed to provide sustained disease remission in most patients suffering from immune-mediated inflammatory diseases (IMIDs). Combining existing drugs could overcome this…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology